Solve this question paper. Use latest medical guidelines and evidences. Don't write long sentances. Give maximum answers in tables, flowchart and diagrams.
endometrial cancer risk classification ESGO ESMO 2021
PORTEC-4a trial endometrial cancer adjuvant treatment
platinum resistant ovarian cancer treatment bevacizumab
Keynote-A18 cervical cancer chemoradiotherapy pembrolizumab
PARP inhibitor recurrent ovarian cancer olaparib niraparib rucaparib
PMID: 41449145
PMID: 38521086
HIPEC ovarian cancer first line randomized trial OVHIPEC
uterine sarcoma classification management WHO 2020
ESGO ESMO 2021 endometrial cancer risk classification molecular TCGA groups
https://www.esgo.org/media/2023/03/Pocket-Guidelines-Endomet…
HIPEC ovarian cancer randomized trial survival
mirvetuximab soravtansine SORAYA MIRASOL platinum resistant ovarian cancer FDA 2022 2023
PMID: 37708912
PMID: 39288779
WHO screening program criteria Wilson Jungner uterine sarcoma classification embryonal rhabdomyosarcoma treatment 2024
brachytherapy advances IGBT MRI guided adaptive ABS GEC-ESTRO 2023 radiation complications management
HIPEC ovarian cancer perioperative complications systematic review
PMID: 39549720
WHO analgesic ladder cancer pain 2022 2023 update step 2 debate malignant bowel obstruction management
Quick Answer Summary
| Q | Topic | Key Evidence Used |
|---|---|---|
| Q1 | EC risk classification + PORTEC-4a | ESGO/ESTRO/ESP 2021; PORTEC-4a (Lancet Oncol 2026, PMID 41449145) |
| Q2 | Platinum-resistant OC | MIRASOL/SORAYA (mirvetuximab FDA 2024); AURELIA (bevacizumab); NCCN 2024 |
| Q3 | WHO ladder + MBO | Fallon 2-step RCT (Ann Oncol 2022); ESMO MBO guidelines |
| Q4 | CCRT rationale + KEYNOTE-A18 | KEYNOTE-A18 PFS (Lancet 2024, PMID 38521086) + OS (Lancet 2024, PMID 39288779) |
| Q5 | HRD/PARPi mechanism + evidence | SOLO-2, NOVA, ARIEL3; Meta-analysis PMID 38409030 (J Ovarian Res 2024) |
| Q6 | WHO screening criteria | Wilson-Jungner 10 criteria; sensitivity/specificity/PPV/NPV framework |
| Q7 | Uterine sarcoma + adolescent ERMS | WHO 2020 classification; IRS/EpSSG VAC protocol |
| Q8 | Brachytherapy advances + complications | IGABT/EMBRACE protocol; GEC-ESTRO 2023; QUANTEC constraints |
| Q9 | HIPEC evidence + complications | OVHIPEC-1 final (PMID 37708912); CHIPOR (PMID 39549720); HORSE trial |
| Q10 | EOL care + bony pain | Single-fraction RT 8Gy; Zoledronic acid/Denosumab; KEYNOTE-826 |